J&J’s innovation strategy has created an industry-leading pipeline and a cycle of success that positions the company for continued growth.
Featured Posts
The leaders at Lilly knew that revenue would be bottoming out last year; with several recent new product approvals and more brewing in the pipeline, things are looking up in Indianapolis.
While Merck’s product sales and financial performance have been less than impressive of late, the company’s pipeline is providing hope for the future.
Novartis has undergone a series of transactions that now concentrate the company on three leading divisions with innovation power and worldwide scale: pharmaceuticals, eye care and generics.
Although price restrictions and lowered reimbursements initially affected the company’s 2014 performance, Novo Nordisk reached one of its long-time pipeline goals with the resubmission and approval of Tresiba in the United States.
After the restructuring of its operations, one key divestment, the acquisition of Hospira and some encouraging pipeline advances, Pfizer executives believe the company is on track for a return to significant growth in the future.
With new CEO Olivier Brandicourt at the helm, launches of new products in 2014 and 2015, pipeline progression, R&D collaborations and the reorganization of the company into a new structure coming in 2016, Sanofi is setting the stage for the future.
Snubbed by its initial takeover target Mylan, Teva moved on by acquiring Allergan’s generic business instead.
Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme’s Lemtrada® (alemtuzumab) in Clinical Trials – In the extension of two Phase […]
How EMRs will – and won’t – change the brand conversation By Gabriel Cangiano, Director, HCP & Payer Strategies, Intouch Solutions [email protected] If electronic medical records didn’t already exist, […]